Everpar Advisors LLC Sells 300 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Everpar Advisors LLC reduced its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 3.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 8,053 shares of the medical device company’s stock after selling 300 shares during the quarter. Everpar Advisors LLC’s holdings in Cooper Companies were worth $740,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC purchased a new stake in Cooper Companies in the 3rd quarter worth approximately $25,000. Covestor Ltd raised its holdings in shares of Cooper Companies by 144.9% during the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 200 shares in the last quarter. Brown Brothers Harriman & Co. lifted its stake in Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares during the period. West Financial Advisors LLC bought a new stake in Cooper Companies in the fourth quarter valued at $49,000. Finally, Friedenthal Financial purchased a new position in Cooper Companies during the 3rd quarter valued at $50,000. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $92.04 on Friday. The Cooper Companies, Inc. has a 1 year low of $84.76 and a 1 year high of $112.38. The firm’s 50-day moving average is $96.75 and its 200 day moving average is $98.85. The stock has a market cap of $18.37 billion, a price-to-earnings ratio of 47.20, a PEG ratio of 2.29 and a beta of 0.99. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.04. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the firm posted $0.87 earnings per share. The business’s revenue was up 9.8% on a year-over-year basis. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Analyst Ratings Changes

COO has been the topic of a number of research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Morgan Stanley cut their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Wells Fargo & Company upped their target price on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. Citigroup lowered their target price on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, December 6th. Finally, StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $117.00.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.